Ben Comer

Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.

Early efforts in the pharma space to harness the engagement factor in game technology focused on delivering a fun experience, with a tackedon educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.

Clayton Christensen, author of "The Innovator's Dilemma", offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations.

A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.

Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.

The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts sa

In late March, the Supreme Court debated the merits-or lack thereof-of the Obama Administration's Patient Protection and Affordable Care Act. Can you match the analogy with the Justice?

If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.

Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon.

Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry.

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday.

On Tuesday, M3 USA’s MDLinx, a pharma advertising supported informational website for physicians, launched a new quiz – The SmartestDoc – for internal medicine and family physicians. In collaboration with MDLinx, the Cleveland Clinic is providing educational materials from its Center for Continuing Education to be used in the quiz,

What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?

This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes.

In judging the Prometheus patents invalid, the Supreme Court may have shown its hand on the upcoming Myriad Genetics case.

Over a hundred public companies, dozens of clinicians, and several regulators participated in investment firm Leerink Swann’s 2012 Healthcare Conference in mid-February.

Jim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world.

SAS’s Brad Sitler talks about the importance of incremental sales, customer proximity, and anticipating a compensation model based on health outcomes

In the rush to collect as much patient data as possible, are we sacrificing quality for quantity? Ben Comer reports.

With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles

So far, the creative approaches industry has taken to develop tamper-resistant and abuse-deterrent opioid drugs have been largely matched by the ingenuity of those users who manage to tamper with and abuse those same formulations.

A new collaboration will move FDA closer to predicting adverse events – before they happen – as part of the regulatory process

At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.

Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.

Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".

Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.

Forget illegal immigrants, it is machines that are stealing American jobs. For some medical practice areas, however, digital details haven’t sufficiently stepped in where their human sales rep predecessors have stepped (or have been pushed) out, according to a survey of U.S. physicians.

Outgoing CEO Michael McCallister said one of Humana’s primary strategies going forward is to keep patients out of hospitals and other healthcare institutions, when possible.